● SK chemicals Announces SKYCellflu`s Clinical Results at ICIC 2015

- SKYCellflu clinical results presented to over 700 international medical professionals
- "Leading the market evolution through superior immunogenicity and safety"



Korea`s first cell-culture influenza vaccine SKYCellflu is making waves in the field of medicine globally.

Man-hun Park, President of SK chemicals announced on the 9th of this month that the company presented performance results of SKYCellflu to the international community of infection experts during ICIC 2015 (International Interscience Conference on Infection and Chemotherapy). The event was held this year from November 5th to 7th at the Lotte Hotel World in Jamsil, Seoul.

ICIC is a biennial international event organized by the Korean Society of Infectious Diseases, and this year marks the second event since its inception. The Conference was attended by 16 scientists from 12 countries including the United States, Japan, Singapore, Sweden, and the United Arab Emirates who addressed the audience, as well as over 700 infection experts from medical communities all over the world.

SK chemicals presented data in evidence of SKYCellflu`s excellent immunogenicity and safety gathered during the drug`s Phase III clinical trials.

Dr. Jun-yeong Song (Professor at the Department of Infectious Diseases at Korea University Guro Hospital) stated during his presentation, "Immunogenicity is critical for vaccines. According to the long-term immunogenicity analysis of SKYCellflu, more than six months of protective immunity is maintained.”

Explaining the clinical results, Dr. Song said, "In terms of effectiveness, SKYCellflu satisfied all criteria defined by the European Medicines Agency (EMA), and immunogenicity was much improved compared to fertilized-egg-based vaccines for influenzavirus B." He added, "Not a single case of serious adverse drug reaction (SADR) has been reported, and there was no difference in rates of adverse reaction compared with the control group."

"There is no risk of external contamination, because SKYCellflu is produced in state-of-the-art sterile incubators, and any component unnecessary for the influenza virus is eliminated in the high-purity vaccine. And because no eggs are used in the manufacturing process, the vaccine is safe for people allergic to eggs."

Prior to this event, SK chemicals announced the results of the clinical trials to medical professionals from around the world at the ICAAC/ICC 2015 organized by the American Academy of Microbiology in San Diego, CA in September. In addition, the adult Phase III clinical trial results were published in Vaccine, a renowned international medical journal.

Just released this August, SKYCellflu has quickly changed the current market paradigm for flu vaccines based on its superior immunogenicity and safety. SK chemicals is already is nearing its target sales goal of 3.7 million doses for the year.

An SK chemicals official said, "We`ve been concentrating our marketing efforts based on SKYCellflu`s performance at home as well as abroad." He anticipated even greater results for the vaccine in the future, stating, "Given that it takes about two weeks for antibody formation after being vaccinated, we`re expecting people to actively seek out vaccination in November."



[Photo]
Dr. Jun-yeong Song from the Department of Infectious Diseases at Korea University Guro Hospital is seen presenting clinical results at the ICIC 2015 held at the Lotte Hotel World in Jamsil, Seoul on November 5th..